<DOC>
	<DOCNO>NCT01351935</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability AVL-292 monotherapy subject relapse refractory B cell non-Hodgkin lymphoma ( B-NHL ) , chronic lymphocytic leukemia ( CLL ) Waldenstrom 's macroglobulinemia ( WM ) .</brief_summary>
	<brief_title>Escalating Dose Study Subjects With Relapsed Refractory B Cell Non-Hodgkin Lymphoma , Chronic Lymphocytic Leukemia , Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>Bruton 's tyrosine kinase ( Btk ) non-receptor tyrosine kinase restrict cellular expression largely limited B-lymphocytes , monocyte , mast cell basophil . Btk critical component B cell receptor ( BCR ) signal network crucial B cell development . Investigation reveal B cell lymphoma CLL depend BCR signaling , suggest interruption signal could promise therapeutic opportunity B-NHL , CLL WM .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Women men ≥18 year age Body weight ≥50 kg . Confirmed diagnosis B cellNonHodgkin Lymphoma ( accord World Health Organization [ WHO ] classification ) include Chronic Lymphocytic Leukemia/Small cell Lymphocytic Leukemia ( International Workshop ) , Waldenstrom 's Macroglobulinemia ( Second International Workshop ) Have fail ≥1 previous treatment BNHL/CLL/WM , relapse refractory disease follow last prior treatment . Eastern Cooperative Oncology Group performance status ≤ 2 life expectancy least 3 month . Ability swallow oral capsule without difficulty Has recover adverse toxic effect prior therapy Meet follow clinical laboratory requirement : Creatinine ≤ 1.5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 x ULN AST ALT ≤ 3 × ULN Platelet count ≥ 50,000/µL ( nonhodgkin &amp; Waldenstrom 's ) Platelet count ≥ 30,000/µL ( chronic lymphocytic leukemia ) Absolute Neutrophil count ≥ 1000/µL Prior allogeneic bone marrow transplant Autologous stem cell transplant within 3 month screen Active central nervous system involvement Subjects autoimmune hemolytic anemia immune thrombocytopenia Prior treatment Btk inhibitor Active uncontrolled infection History malabsorption Uncontrolled illness , i.e cardiac , endocrine , respiratory , etc . History myocardial infarction , acute coronary syndrome , coronary angioplasty and/or stenting previous 6 month History another currently active cancer History major surgery within 4 week minor surgery within 1 week Other medical psychiatric illness organ dysfunction HIV positive Positive Hepatitis B surface antigen Hepatitis Cvirus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>non-hodgkin 's lymphoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>b-cell malignancy</keyword>
	<keyword>Btk inhibitor</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Avila Therapeutics</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
</DOC>